Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study-Reference-Cited by-同舟云学术

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study

Published:2016-03-22 Issue:2 Volume:64 Page:370-380
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Kwo Paul¹,Gitlin Norman²,Nahass Ronald³,Bernstein David⁴,Etzkorn Kyle⁵,Rojter Sergio⁶,Schiff Eugene⁷,Davis Mitchell⁸,Ruane Peter⁹,Younes Ziad¹⁰,Kalmeijer Ronald¹¹,Sinha Rekha¹¹,Peeters Monika¹²,Lenz Oliver¹²,Fevery Bart¹²,De La Rosa Guy¹³,Scott Jane¹⁴,Witek James¹¹

Affiliation:

1. Division of Gastroenterology and HepatologyDepartment of MedicineIndiana UniversityIndianapolis IN

2. Atlanta Gastroenterology AssociatesAtlanta GA

3. Rutgers University, Robert Wood Johnson Medical SchoolNew Brunswick NJ

4. Hofstra North Shore Long Island Jewish School of MedicineManhasset NY

5. Borland‐Groover ClinicJacksonville FL

6. National Research InstituteLos Angeles CA

7. University of Miami Schiff Center for Liver DiseaseMiami FL

8. Digestive CARE‐South Florida Center of GastroenterologyWellington FL

9. Ruane Medical and Liver Health InstituteLos Angeles CA

10. GASTRO ONEGermantown TN

11. Janssen Research and Development LLCTitusville NJ

12. Janssen Infectious Diseases BVBABeerse Belgium

13. Janssen Global Services LLCTitusville NJ

14. Janssen Global Services LLCHigh Wycombe UK

Funder

Janssen

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.28467

Reference22 articles.

1. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir

2. American Association for the Study of Liver Diseases.HCV guidance: recommendations for testing managing and treating hepatitis C.www.hcvguidelines.org/full‐report‐view. Accessed May 5 2015.

3. European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2015.http://www.easl.eu/research/our‐contributions/clinical‐practice‐guidelines/detail/recommendations‐on‐treatment‐of‐hepatitis‐c‐2015. Accessed May 5 2015.

4. Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

5. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis;Nature Communications;2023-11-17

2. Therapeutic Intervention of Serine Protease Inhibitors against Hepatitis C Virus;Current Medicinal Chemistry;2023-10-19

3. Effectiveness of hepatitis C antiviral treatment and feasibility of hepatitis C elimination goal;Postgraduate Medicine;2022-11-04

4. Breakthroughs in hepatitis C research: from discovery to cure;Nature Reviews Gastroenterology & Hepatology;2022-05-20

5. Antivirals against HCV infection: the story thus far;The Journal of Infection in Developing Countries;2022-02-28